About Artax Biopharma
Artax Biopharma is a private company based in Cambridge, Massachusetts. It has reported $55,966,215 raised in eight offerings on Form D since September 2013. Its chief executive is Robert Armstrong, Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Aug 9, 2024amended May 5, 2026 | $19,000,000fully sold | 30 | $633K | Debt, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Dec 17, 2021 | Jan 3, 2022amended May 18, 2022 | $25,785,117fully sold | 28 | $920K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 16, 2021 | Feb 26, 2021 | $2,155,015of $3.0M target | 19 | $113K | Debt, OptionsRule 506(b) | Form D ↗ |
| Apr 17, 2020 | May 4, 2020 | $2,000,000fully sold | 9 | $222K | EquityRule 506(b) | Form D ↗ |
| Jul 31, 2019 | Aug 12, 2019 | $750,000of $3.5M target | 24 | $31,250 | EquityRule 506(b) | Form D ↗ |
| Jul 29, 2015 | Oct 27, 2015 | $3,000,000of $10.0M target | 29 | $103K | EquityRule 506(c) | Form D ↗ |
| Jul 17, 2014 | Nov 10, 2014 | $2,007,827fully sold | 18 | $111K | EquityRule 506(c) | Form D ↗ |
| Jun 24, 2013 | Sep 25, 2013 | $1,268,256of $2.0M target | 19 | $66,750 | DebtRule 506(c) | Form D ↗ |
| Total, eight offerings | $55,966,215 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Artax Biopharma's Form D filed May 5, 2026.
Earlier filings also listed Joseph Lobacki (president and ceo, director, last listed May 2022), Damia Tormo (director, last listed Feb 2021), Javier Garcia (director, last listed May 2020), Damia Tormo, Ph.D., MBM (president and ceo, director, last listed Aug 2019), Peter Finn (secretary, last listed Oct 2015), Henri Termeer (director, last listed Oct 2015) and Jan de Vries, Ph.D. (director, last listed Nov 2014).